Incannex Healthcare Inc. (IXHL)
NASDAQ: IXHL · Real-Time Price · USD
0.4446
-0.0372 (-7.72%)
At close: Oct 6, 2025, 4:00 PM EDT
0.4531
+0.0085 (1.91%)
After-hours: Oct 6, 2025, 7:59 PM EDT
Incannex Healthcare Revenue
In the fiscal year ending June 30, 2025, Incannex Healthcare had annual revenue of $86.00K with 616.67% growth.
Revenue (ttm)
$86.00K
Revenue Growth
+616.67%
P/S Ratio
178.13
Revenue / Employee
$9,556
Employees
9
Market Cap
154.59M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2025 | 86.00K | 74.00K | 616.67% |
Jun 30, 2024 | 12.00K | - | - |
Jun 30, 2023 | - | - | - |
Jun 30, 2022 | 539.05K | -883.65K | -62.11% |
Jun 30, 2021 | 1.42M | 1.01M | 240.67% |
Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
IXHL News
- 5 weeks ago - Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder - GlobeNewsWire
- 6 weeks ago - Incannex Healthcare Authorizes $20 Million Share Repurchase Program - GlobeNewsWire
- 6 weeks ago - Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025 - Update - Newsfile Corp
- 2 months ago - Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea - GlobeNewsWire
- 2 months ago - Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term - GlobeNewsWire
- 2 months ago - Nano-Cap Incannex's Sleep Apnea Candidate Shows Effectiveness And Safety In Mid-Stage Trial - Benzinga
- 2 months ago - Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X - GlobeNewsWire
- 2 months ago - Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo - GlobeNewsWire